- |||||||||| PT886 / Phanes Therap
Phase classification, Trial completion date, Trial primary completion date, Combination therapy, Checkpoint inhibition, Metastases: PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) (clinicaltrials.gov) - Jan 29, 2024 P1/2, N=72, Recruiting, N=72 --> 114 Phase classification: P1 --> P1/2 | Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Nov 2023 --> Dec 2025
- |||||||||| PT886 / Phanes Therap
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Checkpoint inhibition, Metastases: PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) (clinicaltrials.gov) - Dec 1, 2022 P1, N=58, Recruiting, Clinical trial information: NCT02178241. Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Apr 2024 | Initiation date: Aug 2022 --> Nov 2022 | Trial primary completion date: Aug 2023 --> Nov 2023
|